Verma Ajay K, Mishra Mayank, Kant Surya, Kumar Anand, Verma Sushil K, Chaudhri Sudhir, Prabhuram J
Department of Pulmonary Medicine, King George's Medical University (erstwhile C.S.M. Medical University), Lucknow, India.
Lung India. 2013 Oct;30(4):307-11. doi: 10.4103/0970-2113.120606.
Noninvasive mechanical ventilation (NIMV) is the delivery of positive pressure ventilation through an interface to upper airways without using the invasive airway. Use of NIMV is becoming common with the increasing recognition of its benefits.
This study was done to evaluate the feasibility and outcome of NIMV in tertiary care centres.
An observational, retrospective study conducted over a period of 18 months in two tertiary level hospitals of north India on 184 consecutive patients who were treated by NIMV, regardless of the indication. NIMV was given in accordance with the arterial blood gas (ABG) parameters defining respiratory failure (Type 1/Type 2).
The most common indication of NIMV in our hospitals was acute exacerbation of chronic obstructive pulmonary disease (AE-COPD 80.43%), and 90.54% AE-COPD patients were improved by NIMV. Application of NIMV resulted in significant improvement of pH and blood gases in COPD patients, while non-COPD patients showed significant improvement in partial pressure of oxygen (PaO2) alone. The mean duration of NIMV was 8.35 ± 5.98 days, and patients of interstitial lung disease (ILD) were on NIMV for the maximum duration (17 ± 8.48 days). None of the patients of acute respiratory distress syndrome were cured by NIMV; 13.04% patients on NIMV required intubation and mechanical ventilation.
This study demonstrates and encourages the use of NIMV as the first-line ventilatory treatment in AE-COPD patients with respiratory failure. It also supports NIMV usage in other causes of respiratory failure as a promising step toward prevention of mechanical ventilation.
无创机械通气(NIMV)是通过接口对上呼吸道进行正压通气,而不使用侵入性气道。随着对其益处的认识不断提高,NIMV的使用越来越普遍。
本研究旨在评估NIMV在三级医疗中心的可行性和疗效。
在印度北部的两家三级医院进行了一项为期18个月的观察性回顾性研究,对184例连续接受NIMV治疗的患者进行研究,无论其适应症如何。根据定义呼吸衰竭(1型/2型)的动脉血气(ABG)参数给予NIMV。
在我们医院,NIMV最常见的适应症是慢性阻塞性肺疾病急性加重(AE-COPD,80.43%),90.54%的AE-COPD患者通过NIMV得到改善。NIMV的应用使COPD患者的pH值和血气有显著改善,而非COPD患者仅氧分压(PaO2)有显著改善。NIMV的平均持续时间为8.35±5.98天,间质性肺疾病(ILD)患者使用NIMV的时间最长(17±8.48天)。急性呼吸窘迫综合征患者无一通过NIMV治愈;13.04%接受NIMV治疗的患者需要插管和机械通气。
本研究证明并鼓励将NIMV作为呼吸衰竭AE-COPD患者的一线通气治疗方法。它还支持将NIMV用于其他呼吸衰竭原因,作为预防机械通气的有希望的一步。